Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase 2 trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F06%3A00009622" target="_blank" >RIV/00216208:11110/06:00009622 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/06:00001308
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase 2 trial
Original language description
Trastuzumab, vinorelbine, HER-2 positive metastatic breast cancer, first-line chemotherapy
Czech name
Vinorelbin plus trastuzumab v léčbě první linie u nemocných s HER-2 pozitivním metastazujícím karcinomem prsu: mezinárodní studie fáze 2
Czech description
Trastuzumab, vinorelbin, HER-2 pozitivní metastazující karcinom prsu, první linie chemoterapie
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2006
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Cancer
ISSN
0007-0920
e-ISSN
—
Volume of the periodical
—
Issue of the periodical within the volume
August
Country of publishing house
GB - UNITED KINGDOM
Number of pages
6
Pages from-to
1-6
UT code for WoS article
—
EID of the result in the Scopus database
—